Kaletra is FDA approved for the treatment of HIV-1 infection in adult and pediatric patients. Kaletra is a combination of two medications, lopinavir and ritonavir, and is now available in generic.
Kaletra
Package | pill | Total price | Save | Order |
---|---|---|---|---|
250mg × 60 Pills | $4.54 | $272.40 Free Trackable Delivery | - | Add to cart |
250mg × 120 Pills | $4.21 | $505.57 Free Trackable Delivery | $39.60 | Add to cart |
250mg × 180 Pills | $4.10 | $738.75 Free Trackable Delivery | $79.20 | Add to cart |
250mg × 240 Pills | $4.05 | $971.92 Free Trackable Delivery | $117.60 | Add to cart |
250mg × 300 Pills | $4.02 | $1,205.10 Free Trackable Delivery | $156.00 | Add to cart |
250mg × 360 Pills | $4.00 | $1,438.27 Free Trackable Delivery | $194.40 | Add to cart |
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
Kaletra (lopinavir/ritonavir) is prescribed, in combination with other antiretroviral agents, for the treatment of HIV-1 infections in adults and pediatric patients over the age of 14.
Kaletra is available in both oral solution and tablet form. However its generic, lopinavir/ritonavir, is only available as a 160 ml bottle of oral solution.
Overdosage
Overdoses with KALETRA oral solution have been reported. One of these reports described fatal cardiogenic shock in a 2.1 kg infant who received a single dose of 6.5 mL of KALETRA oral solution (520 mg lopinavir, approximately 10-fold above the recommended lopinavir dose) nine days prior. The following events have been reported in association with unintended overdoses in preterm neonates: complete AV block, cardiomyopathy, lactic acidosis, and acute renal failure. Healthcare professionals should be aware that KALETRA oral solution is highly concentrated and therefore, should pay special attention to accurate calculation of the dose of KALETRA, transcription of the medication order, dispensing information and dosing instructions to minimize the risk for medication errors and overdose. This is especially important for infants and young children.
KALETRA oral solution contains approximately 42% (v/v) ethanol and approximately 15% (w/v) propylene glycol. Ingestion of the product over the recommended dose by an infant or a young child could result in significant toxicity and could potentially be lethal.
Human experience of acute overdosage with KALETRA is limited. Treatment of overdose with KALETRA should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with KALETRA. If indicated, elimination of unabsorbed drug should be achieved by gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since lopinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. However, dialysis can remove both ethanol and propylene glycol in the case of overdose with KALETRA oral solution.
Storage
- Store KALETRA oral solution in a refrigerator, between 36°F to 46°F (2°C to 8°C). KALETRA oral solution that is kept refrigerated may be used until the expiration date printed on the label.
- KALETRA oral solution that is stored at room temperature (less than 77°F or 25°C) should be used within 2 months.
- Keep KALETRA oral solution away from high heat.
- Throw away any medicine that is out of date or that you no longer need.
Safety information
Warnings
Risk Of Serious Adverse Reactions Due To Drug Interactions
Initiation of KALETRA, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving KALETRA, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of KALETRA, respectively. These interactions may lead to:
- Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.
- Clinically significant adverse reactions from greater exposures of KALETRA.
- Loss of therapeutic effect of KALETRA and possible development of resistance.
Disclaimer
The information on this page is not intended to be a substitute for professional medical advice. Do not use this information to diagnose or treat your problem without consulting your doctor.
Side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling.
- QT Interval Prolongation, PR Interval Prolongation
- Drug Interactions
- Pancreatitis
- Hepatotoxicity
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions In Adults
The safety of KALETRA has been investigated in about 2,600 patients in Phase II-IV clinical trials, of which about 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily. Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, KALETRA was used in combination with efavirenz or nevirapine.
In clinical studies the incidence of diarrhea in patients treated with either KALETRA capsules or tablets was greater in those patients treated once daily than in those patients treated twice daily. Any grade of diarrhea was reported by at least half of patients taking once daily Kaletra capsules or tablets. At the time of treatment discontinuation, 4.2-6.3% of patients taking once daily Kaletra and 1.8-3.7% of those taking twice daily Kaletra reported ongoing diarrhea.
Amaryl - a medicine of group of sulphonylurea, the peroral hypoglycemic medicine. It has an initially prolonged effect. The mechanism of action consists in stimulation of secretion and release of insulin from beta cells of a pancreas (pancreatic effect). It also increases sensitivity of fatty and muscular tissues to effect of insulin (extrapancreatic effect).
Cialis Soft Tabs differs from a usual tablet of Cialis in the fact that its action comes quicker. Cialis Soft is chewed and dissolved under a tongue that allows to reach a required effect in 10-15 minutes. Important!!! Cialis Soft is compatible to alcohol and greasy food!
Cialis Super Active is a generic drug, against erectile dysfunction, containing 20 mg of tadalafil. The tablets in this series have a gel inside. This form allows the active substance, Tadalafil, to immediately enter the blood, thus providing an immediate effect. The result from the Cialis Super Active tablets appears after 5 minutes! The action lasts for two days. The drug is safe and has virtually no contraindications.
Celexa - antidepressant. Brings energy, stops feeling of alarm, reduces sensation of fear and tension, eliminates dysphoria, reduces persuasive feelings, practically does not cause sedation. The lasting clinical effect develops in 7-10 days of regular reception. The mechanism of action is connected with selective blockade of the return neuronal serotonin reuptake in synapses of neurons of CNS with a minimum effect concerning reuptake of noradrenaline and dopamine.
Fildena is the drug which the main component is Sildenafil Citrate. Sildenafil Citrate was invented for cough treatment but it helped to maintain an erection. That’s how the Viagra was invented. Its invention gave a start to other Sildenafil Citrate analog’s inventions like Fildena. It’s an effective medicine that copes with men’s impotence, premature ejaculation, and diminishes an enlarged prostate. Erectile dysfunction is the result of health problems, exhaustion, bad habits, drug dependence, alcohol abuse, and traumas. Fildena is one of the possible variants of ED treatment.
Finast is indicated for the treatment of benign proliferation of prostate tissue with the purpose of reducing its size and slowing the pathological process. The drug is successfully used to normalize the outflow of urine in case of a benign prostate enlargement and accompanying symptoms of hyperplasia. Finast is recommended for patients with benign enlargement of the prostate for the prevention of complications, urinary retention and the need for surgery. Under the influence of Finast, the level of dihydrotestosterone decreases in the blood and in the tissues of the prostate, but the drug does not affect the androgen receptors.
Keppra - antiepileptic drug, the mechanism of action is unclear, it does not alter normal synaptic transmission. Effective in both focal and epilepsy (epileptiform manifestations, photo paroxysmal reaction).
Peripheral vasodilator with predominant effect on venous vessels. It is used for the prevention of angina in CHF, hypertension in the "small" circulation, "pulmonary" heart (treatment as a part of combination therapy), spasm of peripheral arteries (obliterating endarteritis, angiospastic retinitis)
Xeloda is a cytostatic drug. The drug is used for the treatment of patients with metastatic or locally advanced breast cancer, including after an ineffective chemotherapy course, which included anthracycline drugs and taxanes, and also if the patient has contraindications to anthracyclines.
Danazol is used in endometriosis (with concomitant infertility), benign neoplasms of the breast (fibrocystic mastopathy), primary menorrhagia, premenstrual syndrome, primary premature puberty, gynecomastia.
Alesse is a drug that women take regularly to prevent pregnancy. The medicine contains an estrogen and a progestin. Due to such combination of hormones the ovulation doesn’t occur. The fluid from the vagina gets thicker and prevents ovum fertilization. The drug doesn’t also let the fertilized egg attach to the womb. When the egg doesn’t attach, it will surely leave the body during the menstruation. Pills help to make the menstruation more regular, kill the periodic pain and reduce the amount of blood loss. They are effective in acne treatment and in preventing the risk of ovarian cysts.
Doryx MPC (doxycycline hyclate) delayed-release tablets for oral use, contain doxycycline hyclate, a tetracycline class drug synthetically derived from oxytetracycline, in a delayed-release formulation consisting of pellets with a modified polymer enteric coat that has increased acid resistance.